ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

9.60
0.00 (0.00%)
23 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.60 9.00 10.50 - 0.00 07:30:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.44 89.07M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.60p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £89.07 million. Scancell has a price to earnings ratio (PE ratio) of -7.44.

Scancell Share Discussion Threads

Showing 19476 to 19498 of 65850 messages
Chat Pages: Latest  786  785  784  783  782  781  780  779  778  777  776  775  Older
DateSubjectAuthorDiscuss
07/2/2019
18:30
it's a factorial trial ..

you can argue with Scancell ..

its one product and one trial at phase 1 .. all the regulatory stuff relates to that part of the trial as it dose escalates to the estimated dosage of clinical efficacy

---------------------------------------------------------------------------------

From Lindy and Ruhuls article.. may mean nothing but they say 'clinical trials'... well we know of a 'trial' but 'trials' ?...

'Furthermore, CD4-specific
responses were also observed when these peptides were
tested in vitro using PBMCs from healthy individuals with
several HLA types. The results from PMBCs proliferation
assays suggest the citrullination-specific response is not
restricted to just one HLA type, hence the vaccine can be
used in a wider population. Clinical trials with MODI-1
are now being designed. '

inanaco
07/2/2019
18:25
Crumbs did not state that Modi1 splits into 3 separate trials - you did. Can you confirm whether or not you got this information from Scancell?

The use of the word trials rather than just trial is standard stuff - it's common practice ie. we are going to run clinical trials, we are planning clinical trials.

With the share price sitting at 6p and concerns around how they are going to fund the SCIB1 combination trial let alone just 1 Modi1 trial, it doesn't help anyone to suggest they're going to be running 3.

bermudashorts
07/2/2019
18:10
Ivy, you don't have to answer but with everything that has gone on with this Company why did you decide to buy 50k before the trial has been confirmed. Everyday that passes without IND confirmation is not a good sign.
panama7
07/2/2019
18:09
Bermuda ..

why repeat the debate ?

or do you fancey that ... 3 trials or one trial with 3 arms is a big technical problem for you to handle ?

scancell has called it Trials ...

not me .. argue with Crumbs

i did find the name of the trial design ... cannot remember it now

but for now "factorial Trial" will do ... take it or leave it ...

inanaco
07/2/2019
18:02
Inanaco,

So Scancell will have 3 Moditope clinical trials according to your post on lse?

Oh no, so they will now need 3 trial protocols, CTA applications to MHRA for 3 trials, ethics committee approval for 3 trials, 3 different records on the clinical trials register and most of all FUNDING for 3 separate trials.

Or could it possibly be that following dose escalation Modi1 doesn't split into 3 separate trials as you claim but simply expands into 3 arms of the same trial?

There's a difference. I hope you're just making assumptions and haven't been given this information by Scancell.

bermudashorts
07/2/2019
14:41
Torquay, your 23:53, the horse would be 100/1 if it had never jumped a fence and the Owner, Trainer and Jockey had not given you the full facts.
panama7
07/2/2019
12:17
ONW
That is what the board is all about imo
To be able to post information/ share opinions for open,balanced discussion and not get involved in personal attacks whilst considering all viewpoints.
Great to see how this has evolved on here.

ivyspivey
07/2/2019
12:06
Just reread the replies re LD.
PLEASE no one should ever apologise for posting their own view if a question's been asked. Although I directed it aT Bermuda it's great to get peoples' views from all directions. There's not one that I've seen that I don't have some sympathy for but some I naturally find more appealing (because it suits my own views) but that doesn't make anyone elses view wrong or invalid.
So thanks again all!

oldnotwise
07/2/2019
11:45
I appreciate the comments from all re LD.
I had begun to wonder about the not full time aspect, but I can see the logic in the various points made, and it's an absolute delight to be able to ask and get a varied response and also some insight into the alternative viewpoints that could be mentioned, and addressed.
I particularly like the concept that it's not black and white, and that's a viepoint that I'd begun to lose over time.
So thanks again to everyone that contributed to that "thread" I've got some food for thought from several aspects.
ATB

oldnotwise
07/2/2019
10:32
Strange that Calculus , Scancell's largest Investor have never replaced their voice on the BOD. Glencross telephoned Holloway back in Aug/Sep to be told the trial was on track to commence by end of year. He then tweeted this out to all his followers, he cannot be happy that he was made to look a fool.
panama7
07/2/2019
10:24
Gazza, yeah just a shame she can't convince the Investment or Pharma community.
panama7
07/2/2019
10:23
wonder what the death rate of Dyson users actually is ..
inanaco
07/2/2019
10:19
Most will wither and die in a vacuum.
10acious
07/2/2019
10:17
Ruck ... as you are considered a Space Cadet .. be careful of pest control aerosols while airborne

page 9 of your handbook

LOL

inanaco
07/2/2019
10:09
Anyone recommend a good pest controller?
gazza
07/2/2019
10:08
Bermuda, good reply.The link to the LD article much appreciated too. Nearest thing to immunology for dummies that I have come across- very well explained and illustrated. I liked this bit at the end.."We are certainly closer to curing cancer than we have ever been before. It is not a matter of if, but when, we overcome the challenges of cancer and treatment with vaccines may be one way."Sounds just like something LD would say.
gazza
07/2/2019
10:06
Tosh

Not asking you anything ...

other than prove the CFD trade was matched to the Stock exchange .. """you cannot"""

when most business that trades in CFD uses a Balanced system

ie sells try to match buys while the hedging the difference

but they have Capital buffers and Risk analysis to the individual ..

with something like 80% of the trades on CFD losing money for the client it's like a betting shop ...

but one £10,000 trade is not going to cause stress in the system ..

So you can huff and puff all you like, but you provide no evidence

inanaco
07/2/2019
09:53
Old,

I think it's easy to look at everything to do with Scancell in black and white, good/bad, right/wrong and apply that thought process to the science and BOD alike but in truth it's just far too complex for that, there are so many shades of grey.

As TF, Tosh, Gazza and Ivy have pointed out, there are many practical benefits from LD's dual role and I don't think anyone could question her commitment to the science. On the other hand the downside it does mean that her time and focus is divided between the two.

I suspect that in reality there is far more crossover between the two roles than we realise and rather than switching hats she's probably often wearing them both at the same time. When she's wearing her UoN hat, presenting at conferences, interacting with other KOL's etc. I would guess that her Scancell hat is also visible if that makes sense!

Instead of working in isolation in some remote building, she's working in collaboration and contact with other academics - experts in different fields which gives her (and Scancell) access to more skills and expertise. Much more important and a bigger plus than many appreciate IMO. I'm sure many of Scancell's collaborations are helped along or even born out of her UoN role and contacts - Karolinska and BioNtech spring to mind.

So there are many less tangible benefits from her dual role but also drawbacks. I would imagine that investors, especially US based, will find it hard to see Scancell as a real commercial opportunity rather than funding a tiny early stage bio/academic project whilst they're operating with a part time CSO - not insurmountable but it doesn't make CEO's job any easier.

So I don't think it's a question of good/bad or right/wrong - it just is what it is.

Finally, Sir Greg Winter, Nobel Prize winner, creator of the humanised antibody, founder of the company which created Humira the World's best selling drug etc. etc. has always refused to give up his academic role at Cambridge and he seems to have managed quite well :)

bermudashorts
07/2/2019
09:51
You're not worth spending any more time on... You have had your answer ( many times now ), the fact that you cant understand it merely proves that you dont have the mental capacity to absorb the most basic of information, or indeed , understand your own question, which is fundamentally flawed anyway.

If you understood, you would not be asking such a silly question.

Now disappear... you are not wanted on here.

tosh123
07/2/2019
09:31
a reminder, just so we can see Tosh Freak out again ....

you have provided no facts !!! just lots of Hot Air



inanaco - 06 Feb 2019 - 14:38:15 - 19455 of 19483 Using immunology to fight cancer. - SCLP
No ...

Tosh is talking about hedging the difference between all the CFD options on the table


Researcher 1 ... is talking about a single CFD option on the table

Huge difference

inanaco
07/2/2019
09:02
Gazza, it is nonsense to believe than LD is the only one working in the field of
Cancer that wants to cure all cancers. She most definitely won't be unique in that
respect. As for the links with the UNI, yes there are benefits but there is no doubt
if she was working at Scancell on a full time basis this Science would be much
further down the road. Not one single timescale met in 6 years. Do you think
one of the Investors on Dragon's Den would back a pitcher who had a great idea
but was not prepared to work full time.

panama7
07/2/2019
08:29
Sorry guys, my 19508 crossed with so many new posts that I seem to have resurrected something, but promise, that's MY last on it too.
I'll have a read of the other PROPER posts now and get back later.
Thanks to all,
ATB

oldnotwise
07/2/2019
08:26
Tosh

ATB

oldnotwise
Chat Pages: Latest  786  785  784  783  782  781  780  779  778  777  776  775  Older

Your Recent History

Delayed Upgrade Clock